Bone substitute enters orthopaedic trial:
This article was originally published in Clinica
Executive Summary
ETEX, a biomaterials company based in Cambridge, Massachusetts, has begun a US clinical trial of its Alpha-BSM bone substitute material in non-diaphyseal tibia fractures. The product is already cleared in the US for dental, periodontal and craniofacial applications but approval for orthopaedic applications could open it up to a potential $465 million market. The trial will likely be completed by the beginning of next year, said ETEX.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.